Mumbai, June 22 — The shares of Glenmark Pharmaceuticals on Monday surged days after getting an approval from the Drugs Controller General of India (DCGI) to market and manufacture antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of Covid-19 patients having mild to moderate symptoms.
The shares in the last hour have increased by 15 per cent.The pharmaceutical company’s shares went up to 572.70 in the first half of the session.During clinical trials, the medicine has produced up to 88% improvement in mild to moderate coronavirus patients.It will be available across the country this week, the company said.A pack of 34 oral tablets of 200 mg each will be sold at a cost of Rs 3,500 and the cost of the 14-day treatment will be an estimated Rs 14,000.Image Credit: UnsplashFor any query with respect to this article or any other content requirement, please contact Editor at contentservices@htlive.com
India Blooms
